Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

We’re a month into the year, and there’s so much excitement to come in the Boston-area food and drink world. Below, we’re tracking some of the forthcoming restaurants, bars, bakeries ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical ...

Eli Lilly has announced plans to expand its domestic medicine production in the US by establishing four new pharmaceutical ...

In August 2024, the company opened the research and development hub, Lilly Seaport Innovation Center, in Boston's Seaport district, US. "Eli Lilly to expand US pharma manufacturing with four new ...

Nimbus Therapeutics has been working with Indianapolis drug giant Eli ... The Boston-based biotech recently said it hit a “significant” preclinical milestone in its work with Lilly.

Eli Lilly plans to invest $27 billion in four new pharmaceutical manufacturing facilities in the U.S., expanding its domestic production of medications across multiple therapeutic areas.

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...